Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio que compara Siplizumab con Globulina Anti-Timocítica de Conejo para ayudar al cuerpo a aceptar un trasplante de riñón (MODERNIZE1)

6 de noviembre de 2026 actualizado por: ITB-Med LLC

Estudio de Fase 2b, Aleatorizado, Multicéntrico, Doble Ciego, de Determinación de Dosis, Controlado Activamente de Siplizumab (TCD601) Comparado con Globulina Anti-Timocítica de Conejo en Receptores de Trasplante Renal que Requieren Terapia de Inducción y Reciben el Tratamiento Inmunosupresor Estándar con Tacrolimus, Ácido Micofenólico y Corticosteroides

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:

How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?

How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.

How does the body respond to siplizumab after dosing at each of the 2 dose levels?

How does siplizumab work in the body compared to rATG?

Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.

Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.

Participants will be monitored for 12 months after transplant surgery.

Descripción general del estudio

Descripción detallada

Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.

Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:

  • A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
  • Premedication prior to study treatment infusions.
  • Infection prophylaxis

This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.

Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.

Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.

Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

120

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasil, 30150-320
        • Reclutamiento
        • Santa Casa Demisericordia de Belo Horizonte
        • Contacto:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
        • Reclutamiento
        • Hospital de Clinicas de Porto Alegre
        • Contacto:
      • Porto Alegre, Rio Grande do Sul, Brasil, 90020-090
        • Reclutamiento
        • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
        • Contacto:
    • São Paulo
      • São José do Rio Preto, São Paulo, Brasil, 15090-000
        • Reclutamiento
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
        • Contacto:
      • São Paulo, São Paulo, Brasil, 04038-002
        • Reclutamiento
        • Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
        • Contacto:
          • Research Coordinator
          • Número de teléfono: +55 (11) 5087-8110
          • Correo electrónico: hospital@hrim.com.br
      • Barcelona, España, 08035
        • Reclutamiento
        • Hospital Universitari Vall D'Hebron
        • Contacto:
      • Córdoba, España, 14004
        • Reclutamiento
        • Hospital Universitario Reina Sofía
        • Contacto:
      • Málaga, España, 29010
        • Reclutamiento
        • Hospital Universitario Regional de Malaga
        • Contacto:
    • California
      • Los Angeles, California, Estados Unidos, 90033
        • Reclutamiento
        • Keck Hospital of the University of Southern California
        • Contacto:
      • Los Angeles, California, Estados Unidos, 90095
        • Reclutamiento
        • University of California - Los Angeles, Connie Frank Kidney Transplant Center
        • Contacto:
      • Sacramento, California, Estados Unidos, 95817
        • Reclutamiento
        • UC Davis Medical Center
        • Contacto:
    • Florida
      • Tampa, Florida, Estados Unidos, 33606
        • Reclutamiento
        • Tampa General Hospital
        • Contacto:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University Hospital
        • Contacto:
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Reclutamiento
        • University of Kansas Hospital
        • Contacto:
          • Adam Schooley, MA, CCRP
          • Número de teléfono: 913-588-1699
          • Correo electrónico: aschooley@kumc.edu
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • Reclutamiento
        • University of Kentucky Healthcare
        • Contacto:
          • Malay Shah, MD
          • Número de teléfono: 859-338-1615
          • Correo electrónico: malay.shah@uky.edu
    • Louisiana
      • Metairie, Louisiana, Estados Unidos, 70006
        • Reclutamiento
        • Tulane Medical Center
        • Contacto:
    • Massachusetts
      • Worcester, Massachusetts, Estados Unidos, 01655
        • Reclutamiento
        • UMass Chan Medical Center
        • Contacto:
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Reclutamiento
        • University of Michigan - Michigan Medicine
        • Contacto:
          • Nerissa Reister, Clinical Research Coordinator
          • Número de teléfono: 734-763-5718
          • Correo electrónico: naflow@med.umich.edu
      • Detroit, Michigan, Estados Unidos, 48202
        • Reclutamiento
        • Henry Ford Health
        • Contacto:
          • Matthew Callaghan
          • Número de teléfono: 313-916-4596
          • Correo electrónico: mcallag2@hfhs.org
    • New Jersey
      • Livingston, New Jersey, Estados Unidos, 07039
        • Reclutamiento
        • Cooperman Barnabus Medical Center
        • Contacto:
    • New York
      • New York, New York, Estados Unidos, 10032
        • Reclutamiento
        • New York Presbyterian - Columbia University Irving Medical School
        • Investigador principal:
          • Lloyd Ratner, MD
        • Contacto:
        • Contacto:
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • New York Presbyterian - Weill Cornell Medical Center
        • Contacto:
          • Jennifer Lee
          • Número de teléfono: 212-746-0192
          • Correo electrónico: jel9109@nyp.org
        • Contacto:
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Reclutamiento
        • Duke University Medical Center
        • Contacto:
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • Reclutamiento
        • University of Texas Southwestern Medical Center
        • Contacto:
    • Virginia
      • Falls Church, Virginia, Estados Unidos, 22042
        • Reclutamiento
        • Inova Fairfax Hospital
        • Contacto:
      • Richmond, Virginia, Estados Unidos, 23298
        • Reclutamiento
        • Virginia Commonwealth University Health
        • Contacto:
    • Washington
      • Seattle, Washington, Estados Unidos, 98195
        • Reclutamiento
        • University of Washington Medical Center
        • Contacto:
          • Belinda Pan, Research Coordinator
          • Número de teléfono: 206-598-1562
          • Correo electrónico: bcpan@uw.edu

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Recipients of a renal allograft from a non-HLA identical living or deceased donor.
  • Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.

Exclusion Criteria:

  • Transplant recipients seronegative for EBV.
  • Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
  • Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
  • Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
  • Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
  • ABO-incompatible recipient.
  • Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
  • Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
  • History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
  • Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
  • Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
  • Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
  • Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Siplizumab en dosis baja

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Otros nombres:
  • TCD601
Experimental: Siplizumab en dosis alta

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Otros nombres:
  • TCD601
Comparador activo: Globulina antitimocítica de conejo

An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits

Otros nombres:
  • Timoglobulina

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Periodo de tiempo: 12 months

Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).

12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months
  • Composite incidence of BPAR, death, graft loss, and loss-to-follow-up.
  • Incidence of participants who experienced BPAR as defined by central pathology (blinded independent central review using Banff Allograft Pathology Scoring).
  • Incidence of treated BPAR and steroid-resistant BPAR.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months

• Grade of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months

• Severity of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months
  • Time to first BPAR for each participant.
  • Time to graft loss for each participant.
  • Time to death for each participant.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months
  • Participant survival at 12 months.
  • Graft survival at 12 months.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Periodo de tiempo: 12 months

• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant.

12 months
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Periodo de tiempo: 12 weeks

Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Periodo de tiempo: 12 weeks

Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Periodo de tiempo: 12 months

Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant.

12 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de junio de 2026

Finalización primaria (Estimado)

28 de marzo de 2028

Finalización del estudio (Estimado)

28 de marzo de 2028

Fechas de registro del estudio

Enviado por primera vez

11 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

27 de marzo de 2026

Publicado por primera vez (Actual)

2 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir